Member Info for Digger01

Where is the promised validation study results for Clarava?

Shhhhhh but we seem to be building momentum towards the results of P3 Enhance 2, due this qtr.

Excellent posts!
This is a solid company with cash great assets.
It’s a case of buying cheap for the future as far as I am concerned, paying a nice divi until realisation.

Continued investment from II’s.
Follow the money!
Interims announcement soon.

Does anyone have a link to the actual presentation and I can only find the paper version on the website?

Good progress being made here based on today’s update. Is anybody out there?

I can’t seem to find any information on the website as to who/ what the major holder interests are?
Can anyone point me in that direction?
Secondly, they were on a recruitment drive, is that still happening?

According to FDA, standard response to 510k is 90 days, so hopefully by the end of August.
Further to my previous points, does anyone have any thoughts/info on LSN & Stonechecker? Especially FDA approved LSN

What happened to LSN Software which following FDA approval, shot the SP through the roof late 2020? Also Stonechecker?
All very quiet with focus elsewhere.

I agree! Liquidity has bee low for a while, so I cannot see how the conclusion is reached. However, if one of the main family offloads a few, that’s fine with me,

I note that enrolment for Enhance P3 trials is complete. Enhance 2 data expected Q3 and Enhance 1 at year end. GL all LT holders.

I have bought a few VRNA to average down due to continued belief. I am also very happy that the P3 end point targets are based on FEV and general improvement in well being. FEV has always been good in every previous trial, so I personally believe that the prospects for success are good, and on that basis, I look forward to results

Current SP $4.76 @ £1 = $1.25 = £3.81
8 shares per ADS @ £3.81/8 = £0.476
Then /50 so in “old Aim money” 0.95p
Do still under a penny. I agree that this investment has been a long painful journey, but this year for phase 3 results??

You are correct!
50:1 was a dilution at some point before US listing.
I have held since 2009. I continued to add and need about $20 to break even. Not my best investment!

Last results details 32m in the bank 31/12. No need for a placing!

Only marginally above last high of circa £1.50 pre FDA, so stupidly cheap.

Why not at least give some form of update even if they can’t provide finals? Shareholders deserve better ! Even bad news

Good points made Join/Torn.
Backed up by a great interview posted on Proactive investors https://www.youtube.com/watch?v=4HaoH1z026I

Last update still very positive, I guess it’s recession and default fear that’s holding this back?

From the March update: Based on these comments, I can’t see why anything has fundamentally changed.

Strong start to FY 2022 with 1.8 million sq ft of near-term development starts in Q1 2022, adding a potential £13.1 million of contracted rent, of which 56% has been pre-let.

· FY 2022 guidance increased to 3-4 million sq ft of starts and £350-400 million of capex into development, compared to long-term target run rate of 2-3 million sq ft per annum; maintaining 6-8% target yield on cost.

· Record levels of occupier demand across our portfolio with active negotiations on more than 10 million sq ft over 11 sites.